• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

J&J's Alex Gorsky bagged $26M in pay and perks for 2021, land­ing near the top of the Big Phar­ma CEO lad­der

4 years ago
People
Pharma

SEC is­sues pre­lim­i­nary in­junc­tion against Col­orado biotech ac­cused of $10M fraud

4 years ago
Pharma
Manufacturing

Bev­er­ly Hills plas­tic sur­geon leads phar­ma man­u­fac­tur­ing build in his na­tive Ghana

4 years ago
Pharma
Manufacturing

Pub­li­cis brings back its Health­Front deal­mak­ing mar­ket­place for phar­ma and health­care ad­ver­tis­ers

4 years ago
Pharma
Marketing

Phar­ma in­dus­try rep­u­ta­tion con­tin­ues to slide, ac­cord­ing to new Har­ris Poll. But how low can it go?

4 years ago
Pharma
Marketing

Ne­go­ti­a­tions or price con­trols? Sen­ate Fi­nance Com­mit­tee splits along par­ty lines over drug prices

4 years ago
Pharma

Roche un­corks new long-term da­ta as SMA ri­val­ry heats up

4 years ago
Pharma
Marketing

A wa­tered-down Covid-19 vac­cine IP waiv­er nears the fin­ish line: Will it ac­tu­al­ly ex­pand sup­plies?

4 years ago
Coronavirus
Law

Bio­gen clos­es out its oph­thal­mol­o­gy R&D work, dump­ing off a C3 ther­a­py

4 years ago
R&D

Biotech up­start rides the up­surge in ra­dio­phar­ma R&D to $88M round with mar­quee in­vestors

4 years ago
Financing

Try­ing to nip at As­traZeneca's heels, Lil­ly and Boehringer In­gel­heim stop a PhI­II Jar­diance study ear­ly in kid­ney ...

4 years ago
R&D

Sanofi part­ners up with dom­i­nant ADC play­er Seagen, dou­bling down on on­col­o­gy in hunt for a bet­ter pipeline

4 years ago
Deals
R&D

Der­ma­tol­ogy biotech Krys­tal set­tles law­suit from for­mer part­ner as it pre­pares first FDA pitch

4 years ago
Cell/Gene Tx
Law

With its share price chewed to pieces, Nick Leschly's 2sev­en­ty scores $170M to help weath­er the storm

4 years ago
Financing
Bioregnum

Bio­gen fi­nal­ly pub­lish­es PhI­II re­sults for Aduhelm as crit­ics chas­tise low-rank­ing jour­nal, ‘gen­tle and ...

4 years ago
Pharma

With new RSV an­ti­body, Sanofi looks to avoid a re­peat of a 20-year-old pric­ing con­tro­ver­sy

4 years ago
R&D
Pharma

Back to the fun­da­men­tals: Fra­zier rolls out $1B fund to ramp up a new slate of biotech star­tups

4 years ago
Financing

Biotech founders sen­tenced to 1 year and 1 day for steal­ing Genen­tech se­crets, ly­ing to in­vestors

4 years ago
People
Law

An Al­tos Labs ri­val? Genen­tech throws its hat in­to buzzy 'cel­lu­lar re­ju­ve­na­tion' field

4 years ago
R&D

Pfiz­er pitch­es 4th Covid-19 vac­cine shot for el­der­ly de­spite mixed da­ta from Is­rael

4 years ago
FDA+
Coronavirus

Gov­ern­ment watch­dog ques­tions Eli Lil­ly's cam­paign con­tri­bu­tions

4 years ago
Pharma

No­var­tis, Eli Lil­ly and Ab­b­Vie join grow­ing list of Big Phar­mas sev­er­ing ties with Rus­sia

4 years ago
Pharma

White House sounds the alarm on Covid-19 vac­cine, mon­o­clon­al sup­ply short­ages

4 years ago
FDA+
Coronavirus

Cy­ti­va opens doors at Cardiff site as part of $1.5B glob­al ex­pan­sion

4 years ago
Pharma
Manufacturing
First page Previous page 557558559560561562563 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times